Patents by Inventor Joanna Chmielewska

Joanna Chmielewska has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dimer of molecular variant of apolipoprotein and processes for the production thereof
    Patent number: 6617134
    Abstract: Substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) were isolated from plasma and characterized. Apolipoprotein AI-M dimer can also be produced in a recombinant Escherichia coli system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are described. Patients with atherosclerosis or cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used to prevent thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.
    Type: Grant
    Filed: March 1, 1999
    Date of Patent: September 9, 2003
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Cesare Sirtori, Guido Franceschini, Lars Abrahmsén, Erik Holmgren, Mats Lake, Björn Nilsson, Joanna Chmielewska, Peter Lind
  • Modified coagulation agent
    Patent number: 6069234
    Abstract: The present invention is directed to a modified coagulation factor Xa which has an improved capacity of forming crystals compared to its native form. Such crystals or crystalline composition are especially useful for studies in crystalline form of the active catalytic site of factor Xa when it is complexed to a specific affinity ligand with inhibiting characteristics.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: May 30, 2000
    Assignee: Pharmacia & Upjohn AB
    Inventors: Joanna Chmielewska, Tomas Lundqvist, Erifili Masialou, Derek Ogg
  • Dimer of molecular variant of apolipoprotein and processes for the production thereof
    Patent number: 5876968
    Abstract: Substantially pure dimers of Apolipoprotein Al-Milano (Al-M/APO Al-M) isolated and characterized from plasma are provided. Pharmaceutical compositions comprising the Apo Al-M/Apo Al-M are also provided. Apolipoprotein Al-M dimer can be produced in a recombinant Escherichia coli system or collected from plasma from Apolipoprotein Al-Milano carriers. Atherosclerosis and cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used for preventing thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: March 2, 1999
    Assignee: Pharmacia & Upjohn Aktiebolag
    Inventors: Cesare Sirtori, Guido Franceschini, Lars Abrahmsen, Erik Holmgren, Mats Lake, Bjorn Nilsson, Joanna Chmielewska, Peter Lind